Starpharma Holdings has received US Food and Drug Administration (FDA) approval to begin a Phase II study to investigate VivaGel for the treatment of bacterial vaginosis.
More than 130 women are enrolled on the study, which will identify the efficacy and optimal dosing for VivaGel with three strengths (0.5%, 1% and 3%) compared to a placebo gel.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The trial will observe VivaGel for both short and long-term suppression of bacterial vaginosis recurrence.
Initial phase of the study will analyse a once-daily treatment over seven days.
